Madrigal Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MDGL | RYTM | SEPN | ROIV | VKTX | TARS | |
|---|---|---|---|---|---|---|
| Market cap | 9.30B | 7.67B | 2.23B | 27.61B | 3.57B | 3.23B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 41.6 | -170.1 | -24.7 | -27.5 | -5.5 | -138.1 |
| Price/book | 14.8 | 87.2 | 5.7 | 6.5 | 6.1 | 32.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −16.72% | −13.10% | +128.44% | +78.15% | −28.46% | +6.51% |
| Today | +1.04% | +28.04% | +9.57% | +6.08% | +7.21% | −4.91% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All MDGL news ›Former Madrigal Pharmaceuticals executive alleges coverup of safety issues tied to its drug
Adam Feuerstein is a senior writer and biotech columnist for STAT, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a cohost of STAT's weekly "The Readout LOUD" podcast and the author of…
Madrigal anticipates late 2027 MAESTRO-NASH OUTCOMES readout while planning 2,000+ patient MAESTRO-CSPH study
Madrigal Q3 2026 earnings: Rezdiffra sales surged, profitability turned positive, and F4c trial plans advanced. Earnings Call Insights: Madrigal Pharmaceuticals (MDGL) Q3 2026 CEO William Sibold framed the quarter around accelerating…
Canaccord Genuity Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $612.00. Nash covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Corcept…
Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates
Third Quarter 2026 and Recent Corporate Updates As disease awareness improves and disease prevalence increases, the number of diagnosed patients with F2 to F4c MASH is growing. Madrigal may use its website to comply with its disclosure…
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Tina Ventura - Chief Investor Relations OfficerWilliam Sibold - CEO, President & DirectorDavid Soergel - Executive VP & Chief Medical OfficerMardi…
MDGL Stock Hits Fresh 52-Week Low On Near-Term Profitability Concerns, But Citi Sees Over 75% Upside
MDGL shares were down 6% at the time of writing. CEO Bill Sibold said the company is “still early in a rapidly growing market,” noting the diagnosed U.S. moderate-to-advanced fibrosis population is on track to expand more than 30% in 2026.…
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Jumps 8.9% After Strong Earnings
Posted by Mitch Edgeman on Nov 3rd, 2026 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) rose 8.9% on Tuesday after the company announced better than expected quarterly earnings. The stock traded as high as $482.73 and last…
OSR (NASDAQ:OSRH) versus Madrigal Pharmaceuticals (NASDAQ:MDGL) Head-To-Head Survey
Posted by Mitch Edgeman on Nov 2nd, 2026 Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and OSR (NASDAQ:OSRH – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses…
Madrigal Pharmaceuticals (NASDAQ:MDGL) vs. VistaGen Therapeutics (NASDAQ:VTGN) Critical Survey
Posted by Danessa Lincoln on Nov 1st, 2026 Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) are both healthcare companies, but which is the superior business? We will…
Analysts Are Bullish on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Altimmune (ALT)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Madrigal Pharmaceuticals (MDGL) and Altimmune (ALT) with bullish sentiments. In a report released yesterday, Andrew Fein from H.C. Wainwright…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com7
- seekingalpha.com3
- globenewswire.com2
- ir.madrigalpharma.com2
- blackchronicle.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 25 articles, not a forecast.